Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMS 275
Description: HDAC (Class I) inhibitor
Alternative Names: entinostat,SNDX 275
Chemical Name: (Pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate
Purity: ≥99% (HPLC)
Biological Activity for MS 275
MS 275 is a class I HDAC inhibitor (IC50 values are 0.18, 0.74, 44.9 and >100 μM for HDAC1, 3, 8 and 6, respectively). Exhibits antiproliferative effects and induces apoptosis in a range of tumor cell lines in vitro and in vivo. Increases estrogen receptor α- and aromatase expression in breast cancer cells. Inhibits PCB-induced neuronal cell death by preventing HDAC3 binding and histone deacetylation within the synapsin-1 promoter.
Compound Libraries for MS 275
MS 275 is also offered as part of the Tocriscreen Antiviral Library and Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.
Technical Data for MS 275
| M. Wt | 376.41 |
| Formula | C21H20N4O3 |
| Storage | Store at -20°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 209783-80-2 |
| PubChem ID | 4261 |
| InChI Key | INVTYAOGFAGBOE-UHFFFAOYSA-N |
| Smiles | O=C(C1=CC=C(C=C1)CNC(OCC2=CN=CC=C2)=O)NC3=CC=CC=C3N |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MS 275
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 37.64 | 100 |
Preparing Stock Solutions for MS 275
The following data is based on the product molecular weight 376.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.66 mL | 13.28 mL | 26.57 mL |
| 5 mM | 0.53 mL | 2.66 mL | 5.31 mL |
| 10 mM | 0.27 mL | 1.33 mL | 2.66 mL |
| 50 mM | 0.05 mL | 0.27 mL | 0.53 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for MS 275
References for MS 275
References are publications that support the biological activity of the product.
Saito et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc.Natl.Acad.Sci. 96 4592 PMID: 10200307
Beckers et al (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 121 1138 PMID: 17455259
Formisano et al (2015) MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J.Pharmacol.Exp.Ther. 352 236 PMID: 25467131
Sabnis et al (2011) Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letr. Cancer Res. 71 1893 PMID: 21245100
If you know of a relevant reference for MS 275, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MS 275, MS 275 supplier, MS275, HDAC1, HDAC3, inhibits, inhibitors, class, I, histone, deacetylases, SNDX275, entinostat, SNDX, 275, Class, HDACs, 6208, Tocris Bioscience
2 Citations for MS 275
Citations are publications that use Tocris products. Selected citations for MS 275 include:
Verónica et al (2020) Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo. Neuropharmacology 165 107922 PMID: 31923766
Kim (2018) Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br J Cancer 118 1359 PMID: 29695769
Do you know of a great paper that uses MS 275 from Tocris? Please let us know.
Reviews for MS 275
Average Rating: 5 (Based on 1 Review.)
Have you used MS 275?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
TGF beta high responder treated with 1.5 μM MS 275 (HDAC 3 inhibitor) for 48 h. Cell lysates were analysed by western blot..
By
Anonymous on 11/15/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: C3-TAg tumour cell
TGF beta high responder treated with 1.5 μM MS 275 (HDAC 3 inhibitor) for 48 h. Cell lysates were analysed by western blot.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.